A PLOS Pathogens review explains how liver-resident Kupffer cells capture microbes from flowing blood, kill them ...

On Wednesday, Enveric Biosciences Inc. ENVB, a biotechnology firm developing neuroplastogenic small-molecule therapeutics for ...

Operator: Good day, and thank you for standing by. Welcome to Denali Therapeutics Third Quarter 2026 Earnings Conference Call ...

Geographic atrophy treatment has a new entrant: OliX Pharmaceuticals filed a US IND for OLX301A, a siRNA drug targeting MyD88, the retinal inflammation amplifier Syfovre and Izervay cannot silence.

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic ...

An electrocatalyst that removes excess glucose from the bloodstream could offer a new way to manage type 2 diabetes and ...

Support is available after your IgA nephropathy diagnosis. These IgAN resources offer information, financial assistance, community, and updates on new treatments.

A new review highlights the epidermal growth factor receptor (EGFR) signaling pathway as a central control point for airway ...

With a goal of providing multiple data sets demonstrating differentiated efficacy and safety in multiple ANCA-associated vasculitis (AAV) settings, InflaRx intends to begin two Phase 2 trials in 2027, ...

Patients with generalized myasthenia gravis who responded best to efgartigimod were not the ones with the biggest drop in ...

Periodontitis is driven not only by bacteria but by how the gingival epithelium responds to them. This study maps that ...

Base Case U.S. Market Opportunity Estimated at 15,000 Patients, With Potential to Expand to Approximately 30,000 Patients -- ...